2. Signaling Pathways
  3. GPCR/G Protein
    Neuronal Signaling
  4. 5-HT Receptor
  5. 5-HT4 Receptor Isoform
  6. 5-HT4 Receptor Antagonist

5-HT4 Receptor Antagonist

5-HT4 Receptor Antagonists (14):

Cat. No. Product Name Effect Purity
  • HY-103152
    GR 113808
    		Antagonist 99.96%
    GR 113808 is a potent and highly selective 5-HT4 receptor antagonist (pKb= 8.8). GR 113808 shows 300-fold selectivity over 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2C and 5-HT3 receptors.
  • HY-15574
    Piboserod
    		Antagonist 99.09%
    Piboserod (SB 207266) is a 5-HT4 selective inhibitor of the serotonin receptor.
  • HY-14336A
    SB 271046 Hydrochloride
    		Antagonist 99.93%
    SB 271046 Hydrochloride (SB 271046A) is a potent, selective and orally active 5-HT6 receptor antagonist with pKi of 9.02, 8.55, and 8.81 for rat, pig and human, respectively. SB 271046 Hydrochloride is over 200 fold selective for the 5-HT6 receptor vs 55 other receptors, binding sites and ion channels. Anticonvulsant activity (EC50=0.16 μM).
  • HY-101172
    RS 23597-190
    		Antagonist 99.06%
    RS 23597-190 (EP-A-501322) is a high affinity and selective 5-HT4 receptor antagonist. RS 23597-190 inhibits 5-HT (HY-B1473A)-induced tachycardia. RS 23597-190 significantly inhibits superoxide production in high glucose.
  • HY-101343
    RS 39604
    		Antagonist ≥98.0%
    RS 39604 is a potent, selective, and orally active 5-HT4 receptor antagonist with a pKi of 9.1 in guinea pig striatal membranes. RS 39604 displays a low affinity (pKi<6.5) for 5-HT1A, 5-HT2C, 5-HT3, α1c, D1, D2, M1, M2, AT1, B1 and opioid mu receptors and moderate affinity for δ1, (pKi=6.8) and δ2 (pKi=7.8) sites.
  • HY-105201
    Fabesetron
    		Antagonist
    Fabesetron (FK1052) is an orally active 5-HT3 receptor antagonist with 5-HT4 receptor antagonistic activity. Fabesetron (FK1052) can be used in the study for both acute and delayed emesis induced by cancer chemotherapy.
  • HY-U00121
    Lintopride
    		Antagonist
    Lintopride, a benzamide, is a potent 5HT-4 antagonist with moderate 5HT-3 antagonist properties. Lintopride increases gastric emptying, stimulates antral and duodenal motility and accelerates intestinal transit in animal. Lintopride significantly increases the lower oesophageal sphincter (LOS) basal tone.
  • HY-101638
    (±)-Fabesetron hydrochloride
    		Antagonist
    (±)-Fabesetron hydrochloride ((±)-FK1052) is the racemate of Fabesetron hydrochloride, which is a potent 5-HT3 and 5-HT4 receptor dual antagonist.
  • HY-U00121A
    Lintopride hydrochloride
    		Antagonist
    Lintopride hydrochloride, a benzamide, is a potent 5HT-4 antagonist with moderate 5HT-3 antagonist properties. Lintopride hydrochloride increases gastric emptying, stimulates antral and duodenal motility and accelerates intestinal transit in animal. Lintopride hydrochloride significantly increases the lower oesophageal sphincter (LOS) basal tone.
  • HY-100170
    5-HT4 antagonist 1
    		Antagonist 98.67%
    5-HT4 antagonist 1 is a 5-HT4 receptor antagonist with a pKi of 9.6.
  • HY-105201A
    Fabesetron hydrochloride
    		Antagonist
    Fabesetron (FK1052) hydrochloride is an orally active 5-HT3 receptor antagonist with 5-HT4 receptor antagonistic activity. Fabesetron hydrochloride can be used in the study for both acute and delayed emesis induced by cancer chemotherapy.
  • HY-15574A
    Piboserod hydrochloride
    		Antagonist
    Piboserod (SB 207266) Hcl is a selective 5-HT(4) receptor antagonist.
  • HY-101668
    Sulamserod
    		Antagonist
    Sulamserod is a 5-HT4 receptor antagonist, with antiarrhythmic activities.
  • HY-101668A
    Sulamserod hydrochloride
    		Antagonist
    Sulamserod hydrochloride is a 5-HT4 receptor antagonist. Sulamserod hydrochloride can be used in gastrointestinal disease related research.